WO2001026736A3 - Intraspinal compositions containing botulinum toxin for treating pain - Google Patents

Intraspinal compositions containing botulinum toxin for treating pain Download PDF

Info

Publication number
WO2001026736A3
WO2001026736A3 PCT/US2000/012597 US0012597W WO0126736A3 WO 2001026736 A3 WO2001026736 A3 WO 2001026736A3 US 0012597 W US0012597 W US 0012597W WO 0126736 A3 WO0126736 A3 WO 0126736A3
Authority
WO
WIPO (PCT)
Prior art keywords
botulinum toxin
treating pain
intraspinal
compositions containing
containing botulinum
Prior art date
Application number
PCT/US2000/012597
Other languages
French (fr)
Other versions
WO2001026736A2 (en
Inventor
Kei Roger Aoki
Minglei Cui
Original Assignee
Allergan Sales Inc
Kei Roger Aoki
Minglei Cui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc, Kei Roger Aoki, Minglei Cui filed Critical Allergan Sales Inc
Priority to CA002388681A priority Critical patent/CA2388681A1/en
Priority to DE60016794T priority patent/DE60016794T2/en
Priority to JP2001529797A priority patent/JP4851039B2/en
Priority to DK00932200T priority patent/DK1237566T3/en
Priority to AT00932200T priority patent/ATE284704T1/en
Priority to BR0014710-9A priority patent/BR0014710A/en
Priority to EP00932200A priority patent/EP1237566B1/en
Priority to MXPA02003289A priority patent/MXPA02003289A/en
Priority to AU49954/00A priority patent/AU771536B2/en
Publication of WO2001026736A2 publication Critical patent/WO2001026736A2/en
Publication of WO2001026736A3 publication Critical patent/WO2001026736A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Methods for treating pain by intrathecal administration to a human patient of a therapeutically effective amount of a neurotoxin such as botulinum toxin type A are disclosed.
PCT/US2000/012597 1999-10-12 2000-05-09 Intraspinal compositions containing botulinum toxin for treating pain WO2001026736A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002388681A CA2388681A1 (en) 1999-10-12 2000-05-09 Methods for treating pain
DE60016794T DE60016794T2 (en) 1999-10-12 2000-05-09 INTRASPINAL BOTULINUS-TOXIN-CONTAINING COMPOUNDS FOR PAIN TREATMENT
JP2001529797A JP4851039B2 (en) 1999-10-12 2000-05-09 Pain treatment method
DK00932200T DK1237566T3 (en) 2000-05-09 2000-05-09 Intrinsic compositions containing botulinum toxin for the treatment of pain
AT00932200T ATE284704T1 (en) 1999-10-12 2000-05-09 INTRASPINAL BOTULINUS TOXIN CONTAINING COMPOUNDS FOR PAIN TREATMENT
BR0014710-9A BR0014710A (en) 1999-10-12 2000-05-09 Methods for treating pain
EP00932200A EP1237566B1 (en) 1999-10-12 2000-05-09 Intraspinal compositions containing botulinum toxin for treating pain
MXPA02003289A MXPA02003289A (en) 1999-10-12 2000-05-09 Intraspinal compositions containing botulinum toxin for treating pain.
AU49954/00A AU771536B2 (en) 1999-10-12 2000-05-09 Methods for treating pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/417,195 1999-10-12
US09/417,195 US6113915A (en) 1999-10-12 1999-10-12 Methods for treating pain

Publications (2)

Publication Number Publication Date
WO2001026736A2 WO2001026736A2 (en) 2001-04-19
WO2001026736A3 true WO2001026736A3 (en) 2002-03-21

Family

ID=23652970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012597 WO2001026736A2 (en) 1999-10-12 2000-05-09 Intraspinal compositions containing botulinum toxin for treating pain

Country Status (15)

Country Link
US (4) US6113915A (en)
EP (1) EP1237566B1 (en)
JP (1) JP4851039B2 (en)
KR (1) KR100670479B1 (en)
CN (2) CN1321686C (en)
AR (1) AR021738A1 (en)
AT (1) ATE284704T1 (en)
AU (1) AU771536B2 (en)
BR (1) BR0014710A (en)
CA (1) CA2388681A1 (en)
DE (1) DE60016794T2 (en)
ES (1) ES2231203T3 (en)
MX (1) MXPA02003289A (en)
TW (1) TWI234462B (en)
WO (1) WO2001026736A2 (en)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US7537773B1 (en) 1998-08-25 2009-05-26 Botulinum Toxin Research Associates, Inc. Chemodenervating pharmaceutical as anti-inflammatory agent
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DK1169060T3 (en) * 1999-04-09 2006-01-16 Euro Celtique Sa Sodium channel blocker preparations and their use
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6429189B1 (en) 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
EP1586329A1 (en) * 2000-02-08 2005-10-19 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6821520B2 (en) * 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) * 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US7691983B2 (en) 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6827931B1 (en) 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US20040146590A1 (en) * 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
JP4707254B2 (en) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 Granular composition and method for producing the same
EP1262188A1 (en) 2001-05-22 2002-12-04 Centre National De La Recherche Scientifique (Cnrs) Improved neuronal gene transfer
JP2003009897A (en) 2001-07-03 2003-01-14 Keiji Oguma Method for separating and purifying botulinus toxin
US7438701B2 (en) * 2001-07-26 2008-10-21 Durect Corporation Local concentration management system
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
KR20030018827A (en) * 2001-08-31 2003-03-06 서구일 Sympathetic nerve bl0cking agent comprising botulinum toxin type a, and composition for treatment of the sympathetic nerve related diseases
PT1423168E (en) * 2001-09-03 2006-05-31 Newron Pharm Spa PHARMACEUTICAL COMPOSITION WHICH UNDERSTAND GABAPENTINE OR ITS ANALOGUE AND AN X-AMINOAMIDE AND ITS USE AS ANALGESIC
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
CA2369810C (en) 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US20050106183A1 (en) * 2002-01-31 2005-05-19 Lamb Gregory B. Method of treating pain
WO2003068159A2 (en) * 2002-02-11 2003-08-21 Wake Forest University Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US20030224019A1 (en) * 2002-03-01 2003-12-04 O'brien Christopher Methods of treating nerve entrapment syndromes
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
WO2004016167A1 (en) * 2002-08-16 2004-02-26 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7844338B2 (en) 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US7613515B2 (en) * 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US20040172084A1 (en) 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US8071550B2 (en) * 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
MXPA05009425A (en) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Treatment of sinusitis related chronic facial pain and headache with botulinum toxin.
US20040247623A1 (en) * 2003-03-24 2004-12-09 Roger Cady Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
US20050070970A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Movement disorder stimulation with neural block
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
EP1691835A1 (en) * 2003-11-06 2006-08-23 Icos Corporation Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US7276244B2 (en) * 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
JP5089388B2 (en) 2004-09-01 2012-12-05 アラーガン、インコーポレイテッド Degradable clostridial toxin
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
ES2347581T3 (en) * 2004-09-10 2010-11-02 Newron Pharmaceuticals S.P.A. USE OF (R) - (HALOBENCILOXI) BENCILAMINE-PROPANAMIDS AS SELECTIVE MODULATORS OF THE SODIUM AND / OR CALCIUM CHANNEL.
WO2006101809A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US7731411B2 (en) * 2005-04-04 2010-06-08 Schlumberger Technology Corporation Circulating fluid system for powder fluidization and method of performing same
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20060269574A1 (en) * 2005-05-31 2006-11-30 De Beer Johann F Method of repairing tendons by surgery
US7672727B2 (en) 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US7822486B2 (en) * 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
FR2889936B1 (en) 2005-09-01 2007-12-21 Sod Conseils Rech Applic METHOD FOR QUANTIFYING A CHOLINERGIC NEUROTOXIN IN A SAMPLE
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US9789161B2 (en) * 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
US8916611B2 (en) * 2006-04-28 2014-12-23 Warsaw Orthopedic, Inc. Pharmaceutical removal of neuronal extensions from a degenerating disc
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
FR2902341B1 (en) * 2006-06-16 2011-02-25 Scras THERAPEUTIC USE SIMULTANEOUS, SEPARATE OR SPREAD IN THE TIME OF AT LEAST ONE BOTULINUM NEUROTOXIN, AND AT LEAST ONE OPIACEOUS DERIVATIVE
AR061669A1 (en) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa HIGH FREQUENCY THERAPY APPLICATION WITH BOTULIN TOXIN
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
TW200817015A (en) * 2006-10-06 2008-04-16 Hen-Rich Cheng A method for promoting axonal re-growth and behavior recovery in spinal cord injury
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
FR2907680B1 (en) * 2006-10-27 2012-12-28 Scras THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN IN THE TREATMENT OF PAIN INDUCED BY AT LEAST ONE ANTI-CANCER AGENT
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
FR2910327B1 (en) 2006-12-22 2013-04-26 Scras USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR TREATING PAIN INDUCED BY THERAPEUTIC TREATMENTS OF AIDS VIRUS.
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
FR2930447B1 (en) 2008-04-25 2010-07-30 Sod Conseils Rech Applic THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR THE TREATMENT OF PAIN IN THE CASE OF DIABETIC NEUROPATHY
FR2934267B1 (en) * 2008-07-23 2010-08-13 Pharmaleads AMINOPHOSPHINIC DERIVATIVES USEFUL IN THE TREATMENT OF PAIN
ES2356883B1 (en) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. COMPOSITION FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION.
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
BRPI1013903B1 (en) 2009-04-30 2020-03-03 Midwestern University Use of an adrenergic agent and an endothelin-A antagonist, composition and use of centaquin
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
WO2013009625A1 (en) 2011-07-08 2013-01-17 Allergan, Inc. Method for treatment of autonomic nervous system disorders
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
CN103813802A (en) 2011-07-14 2014-05-21 阿勒根公司 Methods for treatment of incontinence associated with sexual activity
CN103702681A (en) 2011-07-20 2014-04-02 阿勒根公司 Botulinum toxins for use in a method for treatment of adipose deposits
ES2424294B1 (en) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolysaccharide for the treatment and / or care of skin, mucous membranes, hair and / or nails
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
ES2660901T3 (en) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compounds that inhibit neuronal exocytosis (II)
SG11201407784UA (en) 2012-05-30 2014-12-30 Harvard College Engineered botulinum neurotoxin
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
MX370929B (en) 2012-10-28 2020-01-08 Revance Therapeutics Inc Compositions and methods for safe treatment of rhinitis.
US20160045423A1 (en) 2013-03-22 2016-02-18 Lipotec S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
CA3171883C (en) 2013-07-08 2024-03-05 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
CN103520701A (en) * 2013-09-27 2014-01-22 深圳先进技术研究院 Application of A type botulinum toxin in preparation of medicine for preventing neuropathic pains before operation
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
PL3242884T3 (en) 2015-01-09 2021-08-16 Ipsen Bioinnovation Limited Cationic neurotoxins
EP3274364B1 (en) 2015-03-26 2021-08-04 President and Fellows of Harvard College Engineered botulinum neurotoxin
ES2762951T3 (en) * 2015-04-24 2020-05-26 Consiglio Nazionale Ricerche New therapeutic use of serotype A botulinum neurotoxin
US11389483B2 (en) 2015-07-10 2022-07-19 Duke University Methods for treating pain
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
CN105567739B (en) * 2016-02-04 2019-07-12 郑州可尔利尔生物科技有限公司 Vector particles and its construction method and application
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
CN109476713A (en) 2016-06-08 2019-03-15 儿童医学中心公司 Engineered botulic neurotoxin
USD802756S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
EA201990229A1 (en) 2016-07-08 2019-06-28 Пол Стенмарк NEW BOTULINIC NEUROTOXIN AND ITS DERIVATIVES
US11117935B2 (en) 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
CN109790204A (en) 2016-09-29 2019-05-21 益普生生物制药有限公司 Heterozygosis neurotoxin
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
WO2019067815A2 (en) 2017-09-29 2019-04-04 Children's Medical Center Corporation A neurotoxin-like toxin and uses thereof
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
EP3660509B1 (en) 2018-11-29 2022-03-09 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
KR102520625B1 (en) 2019-10-18 2023-04-12 펜랜드 파운데이션 botulinum toxin for use in therapy
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
WO2021231666A1 (en) * 2020-05-15 2021-11-18 Penland Foundation Treatment of asthma using botulinum toxin
WO2021231668A1 (en) * 2020-05-15 2021-11-18 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
CN114957482A (en) 2021-02-26 2022-08-30 重庆誉颜制药有限公司 Modified single-chain polypeptide of neurotoxin and application thereof
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2023287729A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of acute and chronic kidney disease
WO2023287728A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719231A (en) * 1984-05-25 1988-01-12 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai 3-[N-(mercaptoacyl)]amino-4-arylbutanoic acid derivatives and an analgesic agent comprising the same
WO1998001754A1 (en) * 1996-07-08 1998-01-15 University Of Massachusetts Dartmouth Novel proteins within the type e botulinum neurotoxin complex
US5714468A (en) * 1994-05-09 1998-02-03 Binder; William J. Method for reduction of migraine headache pain
US5846216A (en) * 1995-04-06 1998-12-08 G & P Technologies, Inc. Mucous membrane infusor and method of use for dispensing medications

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
JP4381477B2 (en) * 1993-01-15 2009-12-09 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド Method for treating fascial pain syndrome
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
DE19637082A1 (en) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Rapidly disintegrating pellets
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719231A (en) * 1984-05-25 1988-01-12 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai 3-[N-(mercaptoacyl)]amino-4-arylbutanoic acid derivatives and an analgesic agent comprising the same
US5714468A (en) * 1994-05-09 1998-02-03 Binder; William J. Method for reduction of migraine headache pain
US5846216A (en) * 1995-04-06 1998-12-08 G & P Technologies, Inc. Mucous membrane infusor and method of use for dispensing medications
WO1998001754A1 (en) * 1996-07-08 1998-01-15 University Of Massachusetts Dartmouth Novel proteins within the type e botulinum neurotoxin complex

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENOLIEL RAFAEL ET AL: "Actions of intrathecal diphtheria toxin-substance P fusion protein on models of persistent pain.", PAIN, vol. 79, no. 2-3, February 1999 (1999-02-01), pages 243 - 253, XP001012206, ISSN: 0304-3959 *
BERGE O-G ET AL: "SELECTIVE NEUROTOXIC LESIONS OF DESCENDING SEROTONERGIC AND NORADRENERGIC PATHWAYS IN THE RAT", JOURNAL OF NEUROCHEMISTRY, vol. 44, no. 4, 1985, pages 1156 - 1161, XP001011356, ISSN: 0022-3042 *
GARZON J ET AL: "EFFECT OF INTRATHECAL INJECTION OF PERTUSSIS TOXIN ON SUBSTANCE P NOREPINEPHRINE AND SEROTONIN CONTENTS IN VARIOUS NEURAL STRUCTURES OF ARTHRITIC RATS", LIFE SCIENCES, vol. 47, no. 21, 1990, pages 1915 - 1924, XP001011386, ISSN: 0024-3205 *

Also Published As

Publication number Publication date
CN1321686C (en) 2007-06-20
US6333037B1 (en) 2001-12-25
AR021738A1 (en) 2002-08-07
EP1237566A2 (en) 2002-09-11
US6372226B2 (en) 2002-04-16
CN1216639C (en) 2005-08-31
ES2231203T3 (en) 2005-05-16
JP2003514594A (en) 2003-04-22
US6113915A (en) 2000-09-05
US6235289B1 (en) 2001-05-22
AU4995400A (en) 2001-04-23
MXPA02003289A (en) 2002-09-02
TWI234462B (en) 2005-06-21
DE60016794D1 (en) 2005-01-20
KR100670479B1 (en) 2007-01-18
JP4851039B2 (en) 2012-01-11
BR0014710A (en) 2002-06-18
CN1379679A (en) 2002-11-13
CA2388681A1 (en) 2001-04-19
DE60016794T2 (en) 2005-11-24
WO2001026736A2 (en) 2001-04-19
EP1237566B1 (en) 2004-12-15
US20010012828A1 (en) 2001-08-09
CN1683004A (en) 2005-10-19
KR20020048956A (en) 2002-06-24
AU771536B2 (en) 2004-03-25
ATE284704T1 (en) 2005-01-15

Similar Documents

Publication Publication Date Title
WO2001026736A3 (en) Intraspinal compositions containing botulinum toxin for treating pain
WO2001078760A3 (en) Method for treating pain by peripheral administration of a neurotoxin
WO2001095924A3 (en) Method for treating a movement disorder
WO2002007759A3 (en) Clostridial toxin derivatives and methods for treating pain
WO2000051623A3 (en) Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
CA2296720A1 (en) Use of botulinum toxin in the preparation of a pharmaceutical composition for treating a prostate disorder in a mammal
AU2001251546A1 (en) Method for treating pain by peripheral administration of a neurotoxin
DE60323628D1 (en) INTRAKRANIAL TREATMENT OF NEUROPSYCHIATRIC DISEASES WITH CLOSTRIDIUM NEUROTOXINES SUCH AS BOTULINUS TOXIN
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
PT1365762E (en) Method for increasing leptin levels using nicotinic acid compounds
YU59198A (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
WO2000018419A3 (en) Methods for administration of antibiotics
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2002018334A3 (en) Sodium channel modulators
CA2301742A1 (en) 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
CA2283399A1 (en) Pyridazinones as inhibitors of cyclooxygenase-2
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
WO2001081332A3 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
AU2002227052A1 (en) Treatments for neurogenetic disorders, impulse control disorders, and wound healing
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
CA2211320A1 (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
WO1999045909A3 (en) Use of nitrone compounds for the inhibition of angiogenesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003289

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 529797

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000932200

Country of ref document: EP

Ref document number: 1020027004558

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 49954/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2388681

Country of ref document: CA

Ref document number: 008142572

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027004558

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000932200

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 49954/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000932200

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020027004558

Country of ref document: KR